Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Bristol-Myers Squibb Co.’s stock rose 2.9% early Thursday, after the drug company posted better-than-expected third-quarter earnings and raised its guidance. Princeton, N.J.-based Bristol Myers had ...

Bristol Myers Squibb (BMY) is set to announce Q3 earnings. Analysts expect profit of $1.50 per share on revenue of $11.25B.

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...

It continued: "The IRA does not protect patients from potential increases to their cost sharing or restrictions in access to Eliquis once the MFP goes into effect in January 2026. By focusing on ...